Affiliation:
1. State Key Laboratory of Toxicology and Medical Countermeasures; Beijing Institute of Pharmacology and Toxicology; 27 Taiping Road Beijing 100850 China
2. The International Therapy Center for Liver Disease; Military 302 Hospital; Beijing 100039 China
Funder
National Natural Science Foundation of China
National Science and Technology Major Projects for Major New Drugs Innovation and Development of China
National Key New Drug Creation Program
Reference50 articles.
1. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase;Ahmed-Belkacem;Gastroenterology,2010
2. HCV natural history: the retrospective and prospective in perspective;Alter;J Hepatol,2005
3. Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle;Althagafy;Bioorg Med Chem,2013
4. Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers;Ashby;J Antimicrob Chemother,2011
5. Inhibition of HCV 3a core gene through Silymarin and its fractions;Ashfaq;Virol J,2011a
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献